Growth Hormone Axis Research

The growth hormone axis is a hypothalamic-pituitary-liver cascade: GHRH stimulates pituitary somatotrophs to release GH, which stimulates hepatic IGF-1 production. IGF-1 then mediates most of GH's growth-promoting effects via the IGF-1 receptor (IGF-1R) and downstream PI3K/AKT/mTOR signaling.

**CJC-1295** is a synthetic GHRH analog that binds the GHRH receptor on somatotrophs. **Ipamorelin** is the most selective GHSR (ghrelin receptor) agonist in the literature, stimulating GH release without significant ACTH/cortisol/prolactin cross-activation.

Together, CJC-1295 + Ipamorelin activate complementary GH-secretion pathways — a standard research pairing for studying pulsatile GH release and GH-axis selectivity.

**IGF-1 LR3** bypasses the axis entirely. It's a recombinant IGF-1 analog with an N-terminal extension and Arg-3 substitution that dramatically reduces IGFBP binding, increasing free-receptor availability and prolonging effective half-life. Standard assays include IGF-1R phosphorylation Westerns in C2C12 myoblasts and myotube formation kinetics.

All growth-axis peptides are verified by Janoshik for purity (≥98–99%) and identity (ESI-MS ±1 Da).